Alembic Pharma Strengthens US Presence with Key Oncology Approval

Alembic Pharmaceuticals Limited (

) has secured final approval from the US Food and Drug Administration for its generic Methotrexate Injection USP, marking a strategic expansion in its oncology and specialty portfolio. The approval, granted under the abbreviated new drug application (ANDA) pathway, covers key dosage strengths including 50 mg/2 ml multi-dose vials and 1 g/40 ml single-dose vials, with the product deemed therapeutically equivalent to the reference drug by Hospira. This injectable is widely used in the treatment of multiple cancers such as leukemia, osteosarcoma, breast cancer, and head & neck cancers, along with autoimmune conditions like rheumatoid arthritis and severe psoriasis. With this nod, the company can now commercially launch the product in the United States, one of the largest pharmaceutical markets globally, enhancing its revenue visibility and strengthening its complex generics pipeline. Notably, this approval adds to Alembic’s growing regulatory track record, taking its cumulative ANDA approvals to 236 (including 218 final approvals and 18 tentative approvals), reinforcing its position in the high-value injectable segment. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.